Eli Lilly's Strategic Moves to Address Patent Cliff Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy LLY?
Source: Fool
- GLP-1 Market Performance: Eli Lilly, as the leading manufacturer of GLP-1 drugs, has seen a 225% stock price increase over the past three years, yet its price-to-earnings ratio has soared to 49, with a meager 0.6% dividend yield, indicating market over-optimism regarding short-term performance.
- Sales Growth and Dependency: In 2025, sales of Mounjaro and Zepbound surged by 99% and 175% respectively, but these two drugs accounted for 56% of the company's sales, creating a heavy reliance on their continued success for future revenue.
- Patent Risks and Market Challenges: The limited patent protection period for new drugs poses a significant risk, as generic alternatives will enter the market post-patent expiration, leading to a sharp decline in sales, thus Eli Lilly faces the looming threat of a patent cliff.
- Strategic Investments and Acquisitions: To mitigate the patent cliff risk associated with GLP-1 drugs, Eli Lilly is leveraging its GLP-1 revenue to invest in new opportunities, partnering with Seamless Therapeutics for gene editing technology and acquiring Ventyx Biosciences for oral inflammation treatments, reflecting its strategic intent for diversified investments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 927.030
Low
950.00
Averages
1192
High
1500
Current: 927.030
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
See More
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
See More
Eli Lilly's GLP-1 Drug Sales Surge Remarkably
- Significant Sales Growth: Eli Lilly's Mounjaro and Zepbound GLP-1 drugs saw sales increases of 99% and 175% in 2025, respectively, showcasing the company's strong performance in the rapidly growing weight-loss drug market and further solidifying its market leadership.
- Outstanding Stock Performance: Over the past decade, Eli Lilly's stock has surged more than 1,100%, significantly outperforming the S&P 500's 230% increase, reflecting strong investor confidence in its future growth, although its current P/E ratio of 39x remains above the industry average.
- Intensifying Competitive Risks: Despite Eli Lilly's leading position in the GLP-1 space, competitors like Novo Nordisk and Pfizer are actively launching new products, which could erode Eli Lilly's market share, especially as patents expire and generics emerge, potentially impacting revenues significantly.
- Strategic Acquisition Moves: To address future competition and risks, Eli Lilly is leveraging the windfall from its GLP-1 success to pursue strategic acquisitions, which may help diversify its product pipeline, but the uncertainty surrounding the success of these new drugs could affect the company's long-term growth potential.
See More
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
ELI LILLY IN FINAL DISCUSSIONS TO PURCHASE KELONIA THERAPEUTICS FOR OVER $2 BILLION - WSJ
- Eli Lilly's Acquisition Talks: Eli Lilly is engaged in advanced discussions to acquire Kelonia Therapeutics.
- Financial Implications: The potential acquisition is valued at over $2 billion.
See More
ELI LILLY CLOSES IN ON AGREEMENT WITH CANCER BIOTECH FIRM - WSJ
Eli Lilly's Cancer Deal: Eli Lilly has reached a significant agreement in the cancer biotechnology sector, indicating a strategic move to enhance its portfolio in oncology treatments.
Impact on Biotechnology: This deal is expected to influence the biotechnology landscape, potentially leading to advancements in cancer therapies and improved patient outcomes.
Market Reactions: The announcement has garnered attention from investors and analysts, reflecting optimism about Eli Lilly's future growth and innovation in cancer treatment.
Future Developments: Further details on the specifics of the deal and its implications for Eli Lilly's research and development efforts are anticipated in upcoming reports.
See More
